ABSTRACT
In the human genome, most 5' splice sites (~99%) employ the canonical GT dinucleotide whereas a small minority (~1%) use the non-canonical GC dinucleotide. The functionality and pathogenicity of 5' splice site GT>GC (i.e., +2T>C) variants have been extensively studied but we still know very little about 5' splice site GC>GT (+2C>T) variants. Herein, we sought to address this deficiency by performing a meta-analysis of identified +2C>T pathogenic variants together with a functional analysis of +2C>T substitutions using a cell culture-based full-length gene splicing assay. Our results establish a proof of concept that +2C>T variants are qualitatively different from +2T>C variants in terms of their functionality and pathogenicity and suggest that, in sharp contrast with +2T>C variants, most if not all +2C>T variants have no pathological relevance. Our findings have important implications for interpreting the clinical relevance of +2C>T variants but might also improve our understanding of the evolutionary basis of switching between GT and GC 5' splice sites in mammalian genomes.
KEYWORDS
+2C>T variant, full-length gene splicing assay, Human Gene Mutation Database, human inherited disease, 5' splice site, +2T>C variant In the human genome, the vast majority (>99%) of introns are of the U2 type. Most of these (~99%) employ the canonical 5' splice site GT dinucleotide whereas a minority (~1%) use the non-canonical 5' splice site GC dinucleotide (Abril et al., 2005; Burset et al., 2000 Burset et al., , 2001 Parada et al., 2014; Sheth et al., 2006) . 5' splice site GT>GC (or +2T>C) variants have been frequently described as causing human genetic disease (Stenson et al., 2017) and are routinely scored as splicing mutations (Mount et al., 2019) . However, we have recently provided evidence that such variants in human disease genes may not invariably be pathogenic.
Specifically, combining data derived from a meta-analysis of human disease-causing +2T>C variants and a cell culture-based Full-Length Gene Splicing Assay (FLGSA) of +2T>C substitutions, we estimated that ~15-18% of +2T>C variants generate up to 84% normal transcripts . In another recent study, the functional effects of over 4000 BRCA1 variants were analyzed by means of saturation genome editing (Findlay et al., 2018) .
Of these variants, 12 were noted to be of the +2T>C type; 25% (n = 3) of these +2T>C variants generated wild-type transcripts, a proportion which is not inconsistent with our estimated 15-18% rate. By contrast, we know very little about 5' splice site GC>GT (or +2C>T) variants. Herein, we aimed to bridge this gap by performing a meta-analysis of identified "pathogenic" +2C>T variants and a functional analysis of artificially engineered +2C>T substitutions.
We first examined three +2C>T variants, C1orf127 c.1290+2C>T, DMD c.4233+2C>T and THSD7B c.2396+2C>T (Table 1) , logged in the Professional version of the Human Gene Mutation Database (HGMD; http://www.hgmd.org; as of August 2019) (Stenson et al., 2017) .
Both C1orf127 c.1290+2C>T and THSD7B c.2396+2C>T were identified by exome sequencing 933 subjects with autism spectrum disorders (ASD) and 869 controls; each variant was only found in a single case and in the homozygous state, corresponding to a minor allele frequency (MAF) of 0.0011 in the context of cases (Lim et al., 2013) . These and other "rare complete gene knockouts" were considered to be important inherited risk factors for ASD by the original authors. However, as shown in Table 1 , both variants occur at polymorphic frequencies in the non-Finnish European population and across all gnomAD populations (https://gnomad.broadinstitute.org/) (Lek et al., 2016) . DMD c.4233+2C>T was found in three of 2071 ASD cases (MAF of 0.00072) but not in 904 controls of European white ancestry by means of targeted massively parallel sequencing of ASD-associated genes; it was considered to be a rare loss-of-function risk variant for ASD (Griswold et al., 2015) . However, this variant has a MAF of 0.00073 in non-Finnish Europeans and a MAF of 0.00067 across all gnomAD populations (Table 1) . Moreover, the variant is registered in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), wherein it is interpreted as being "Benign/Likely benign". A search for "+2C>T" plus "mutation" or "variant" via Google (as of October 18, 2019) yielded an additional three +2C>T variants, COL4A4 c.1459+2C>T, EYA1
c.1360+2C>T and MUTYH c.1476+2C>T; they were all registered in ClinVar and almost invariably interpreted as being of "uncertain significance" ( Table 1) . Although the number (n = 6) of +2C>T variants identified to date is very limited, they serve to illuminate the problems of interpretation inherent to the +2C>T variants as a whole. This is due to the paucity of our knowledge about the functional effects of +2C>T variants on splicing.
Employing cell culture-based FLGSA, we have previously analyzed the functional impact of 103 +2T>C variants. 82% of these variants resulted in the generation of only aberrantly spliced transcripts. The other 18% of variants retained some ability to generate wild-type transcripts but none was capable of generating a transcript level equal to or higher than its wild-type counterpart . Herein, we employed the same experimental model system to analyze engineered +2C>T substitutions ( Fig. 1a; Supplementary Table S1 ). All experiments were performed as previously described . Primer sequences used to amplify the full-length genes and perform mutagenesis and sequencing are available upon request. Whereas the Human Genome Variation Society (HGVS) nomenclature (den Dunnen et al., 2016) was used for clinically identified variants, the traditional IVS (InterVening Sequence; i.e., an intron) nomenclature was used for the engineered substitutions in accordance with our previous publication .
We succeeded in analyzing 15 +2C>T substitutions from 15 different genes by in vitro expression analysis. Their functional impact contrasted with that of the +2T>C substitutions in two respects. First, all 15 +2C>T substitutions generated the same transcript band(s) as their wild-type counterparts ( Fig. 1b and Supplementary Fig. S1) . Second, only wild-type transcripts were observed for 12 of the 15 +2C>T substitutions (and their wild-type counterparts). We quantified the relative levels of the normally spliced transcripts for these 12 +2C>T substitutions by means of quantitative RT-PCR analysis as previously described , with the results being summarized in Fig. 1c . For the remaining three +2C>T substitutions (i.e., CDRT15 IVS2+2C>T, EIF1AD IVS1+2C>T and PRSS3 IVS1+2C>T), the relative level of the normally spliced transcripts was estimated to be approximately the same as the wild-type based upon visual inspection of the intensities of the wild-type and additional transcripts bands (Supplementary Fig. S1 ). Thus, 87% (n = 13) of the 15 +2C>T substitutions generated an equal or even higher level of normal transcripts as compared to that of their corresponding wild-type alleles (Fig. 1c) . These findings are consistent with the expectation that any +2C>T substitutions in GC 5' splice sites will increase the complementarity between the 9-bp consensus sequence for the U2-type 5' splice site and the 3'-GUCCAUUCA-5' sequence at the 5' end of U1 snRNA (see and references therein). Nonetheless, two +2C>T substitutions, TMED4 IVS4+2C>T and TUBB IVS4+2C>T, generated a much lower level of normal transcripts as compared to their wildtype alleles (Fig. 1c ), suggesting the possible involvement of sequence determinants for splicing beyond the short 9-bp consensus sequence motif.
In summary, we establish a proof of concept that +2C>T variants behave differently from +2T>C variants in relation to the resulting splicing phenotype. Our findings suggest that, in sharp contrast with +2T>C variants, most if not all +2C>T variants have no pathological relevance. This conclusion has immediate implications for interpreting the clinical relevance of 5' splice site GC>GT variants but should also help us to understand the process of evolutionary switching between GT and GC 5' splice sites in mammalian genomes (Abril et al., 2005) .
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Table 1. Description of the clinically identified germline 5' splice site GC>GT (+2C>T) variants
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